

Malignant extracranial germ cell tumours: A first national report by the South African Children's Cancer Study Group

Marc Hendricks^{1,*}, Annibale Cois^{2,13}, Jennifer Geel³, Johan du Plessis⁴,
Mairi Bassingthwaight⁵, Gita Naidu⁵, Bianca Rowe⁵, Ané Büchner⁶, Fareed Omar⁶,
Karla Thomas⁷, Ronelle Uys⁸, Anel van Zyl⁸, Jaques van Heerden^{8,12}, Ngoakoana
Mahlachana⁵, Johani Vermeulen⁹, Alan Davidson¹, A. Lindsay Frazier¹⁰, KirstyDonald¹¹,
Mariana Kruger⁸

¹Haematology Oncology Service, Department of Paediatrics and Child Health, Red Cross War Memorial Children's Hospital, University of Cape Town, Cape Town, South Africa

²Division of Health Systems and Public Health, Department of Global Health, Stellenbosch University, Cape Town, South Africa

³Division of Paediatric Haematology Oncology, Department of Paediatrics and Child Health, Charlotte Maxeke Johannesburg Academic Hospital, University of Witwatersrand, Johannesburg, South Africa

⁴Division of Paediatric Haematology Oncology, Department of Paediatrics, Universitas Hospital, University of the Free State, Bloemfontein, South Africa

⁵Division of Paediatric Haematology Oncology, Chris Hani Baragwanath Academic Hospital, University of Witwatersrand, Soweto, South Africa

⁶Paediatric Haematology Oncology, Department of Paediatrics, Steve Biko Academic Hospital, University of Pretoria, Tshwane, South Africa

⁷Paediatric Haematology Oncology, Department of Paediatrics and Child Health, Frere Hospital, East London, South Africa

⁸Paediatric Haematology Oncology, Department of Paediatrics and Child Health, Faculty of Medicine and Health Sciences, University of Stellenbosch, Tygerberg Hospital, Cape Town, South Africa

⁹Paediatric Haematology Oncology, Department of Paediatrics and Child Health, Port Elizabeth Provincial Hospital, Walter Sisulu University, Port Elizabeth, South Africa

¹⁰Paediatric Oncology, Dana-Farber Cancer Institute/Boston Children's Cancer and Blood Disorder Centre, Harvard University, Boston, Massachusetts, USA

¹¹Division of Developmental Paediatrics, Department of Paediatrics and Child Health, Red Cross War Memorial Children's Hospital, and Neuroscience Institute, University of Cape Town, Cape Town, South Africa

¹²Paediatric Haematology and Oncology, Department of Paediatrics and Child Health, University of Antwerp, Antwerp University Hospital, Antwerp, Belgium

¹³Division of Epidemiology and Biostatistics, School of Public Health and Family Medicine, University of Cape Town, Cape Town, South Africa

*Correspondence: Marc Hendricks, Room 48, G1OPD, Haematology Oncology Service, Red Cross War Memorial Children's Hospital, Klipfontein Rd, Rondebosch, South Africa 7700. Email: Marc.Hendricks@uct.ac.za

SIOP International, Lyon, France (Poster): Hendricks M, Cois A, du Plessis J, Geel J, van Heerden J, Naidu G, Bassingwaighte M, Rowe, B, van Zyl A, Uys R, Büchner A, Omar F, Thomas K, Machlachana N, Vermeulen J, Davidson A, Donald K, Kruger M. Favourable outcomes for children with biopsy-proven malignant extracranial germ cell tumours 1990–2015: A first national report by the South African Children's Cancer Study Group (SACCSG). *Pediatr Blood Cancer*. 2019;66(11); SIOP 19-0822.

ABSTRACT

Objective: To determine the overall survival (OS) and prognostic factors influencing outcomes in children and adolescents with malignant extracranial germ cell tumours (MEGCTs) in preparation for the development of a harmonised national treatment protocol.

Methods: A retrospective folder review was undertaken at nine South African paediatric oncology units to document patient profiles, tumour and treatment-related data and outcomes for all children with biopsy-proven MEGCTs from birth up to and including 16 years of age.

Results: Between 1 January 2000 and 31 December 2015, 218 patients were diagnosed with MEGCTs. Female sex (hazard ratio [HR] 0.284, $p = .037$) and higher socio-economic status (SES) (HR 0.071, $p = .039$) were associated with a significantly lower risk of death. Advanced clinical stage at diagnosis significantly affected 5-year OS: stage I: 96%; stage II: 94.3%; stage III: 75.5% ($p = .017$) and stage IV (60.1%; $p < .001$). There was a significant association between earlier stage at presentation and higher SES ($p = .03$). Patients with a serum alpha-fetoprotein (AFP) level of more than 33,000 ng/ml at diagnosis had significantly poorer outcomes ($p = .002$). The use of chemotherapy significantly improved survival, irrespective of the regimen used ($p < .001$).

Conclusions: The cohort demonstrated a 5-year OS of 80.3% with an event-free survival (EFS) of 75.3%. Stage, the use of chemotherapy and an elevated serum AFP level of more than 33,000 ng/ml were independently predictive of outcome. The relationship between SES and outcome is important as the implementation of the new national protocol hopes to standardise care across the socio-economic divide.

Keywords: malignant extracranial germ cell tumours, paediatric

Abbreviations

AFP	alpha-fetoprotein
BEP	bleomycin, etoposide, cisplatin
EFS	event-free survival
GFR	glomerular filtration rate
HR	hazard ratio
JEb	carboplatin, etoposide, bleomycin (paediatric)
LMICs	low- and middle-income countries
MEGCTs	malignant extracranial germ cell tumours
OS	overall survival

PEb	cisplatin, etoposide, bleomycin (paediatric)
POUs	paediatric oncology units
SACCSG	South African Children's Cancer Study Group
SD	standard deviation
SES	socio-economic status
WHO	World Health Organization

1 INTRODUCTION

Malignant extracranial germ cell tumours (MEGCTs) represent a biologically heterogeneous group of malignancies with manifestation influenced by age, sex, site and the relationship of the tumour to puberty, although histologically they may be similar between sites.^{1, 2} MEGCTs are rare and comprise approximately 3% of all childhood tumours.³ However, the incidence rises sharply at the time of puberty, and MEGCTs are the most common solid tumours in adolescents and young adults exhibiting similar behaviour.⁴ Traditional treatments included mainly surgery and chemotherapy, although testicular and mediastinal seminomas⁵ (which are rare in children) and ovarian dysgerminomas are radiotherapy sensitive. The improved efficacy of chemotherapy regimens over time eclipsed the need for radiotherapy where undue toxicity could be avoided or minimised with chemotherapy alone. Consequently, radiotherapy has not been incorporated into first-line treatment regimens in children. Instead radiotherapy continues to be used for refractory or relapsed tumours as a salvage strategy for poor chemotherapy responders, and even then has not been shown to add significant benefit.⁶

Einhorn and Donohue pioneered the first multiagent chemotherapy regimens in adults with metastatic testicular disease in the late 1970s, initially using cisplatin, vinblastine and bleomycin, which demonstrated impressive complete remission rates (80% and 74%, respectively).^{7, 8} Since that time, several co-operative groups have used similar platinum backbones to refine chemotherapy approaches first in adults and then in paediatrics.⁹⁻¹² Over time, renal and ototoxicity prompted a switch from cisplatin to carboplatin, with etoposide and bleomycin (JEB),¹⁰ which had been shown to be highly efficacious and less toxic by earlier investigators.^{11, 12} Subsequently, Jeb (carboplatin, etoposide, bleomycin [paediatric]) and PEb (cisplatin, etoposide, bleomycin [paediatric]) have been shown to have equivalence in the treatment of standard-risk MEGCTs in children.¹³

There are less data reported from low- and middle-income countries (LMICs), where resources are constrained and reliable paediatric cancer registries are confined to single institutions or do not exist at all.¹⁴ Recent data from the South African Children's Tumour Registry reported an age-standardised ratio (ASR) of 1.7/1,000,000 for MEGCTs.¹⁵ Where data from LMICs are available, studies have shown comparable outcomes to high-income countries (HICs). In South Africa, these reports are limited to single institutions and have been shown to be appropriate, cost-effective and efficacious.¹⁶ No published series exists that has investigated potential prognostic factors and treatment outcomes for MEGCTs in African paediatric populations, in particular the relationship between poverty and cancer outcomes. Rather, risk factors have been extrapolated from pooled data from much larger international collaborative groups in HICs.^{17, 18} As a preamble to the development of a national treatment

protocol, the South African Children's Cancer Study Group (SACCSG) undertook a national retrospective review of all children 16 years and under with biopsy-proven MEGCTs.

2 METHODS

2.1 Patients

Nine paediatric oncology units (POUs) across South Africa participated in the national retrospective study from the public and private sectors. Anonymised demographic and treatment-related data were collected at each site for all children with biopsy-proven disease up to and including the age of 16 years, and included age, sex, anthropometry, symptom profiles, comorbidities, stage, tumour site, histology, tumours markers, imaging techniques, response assessments at first review, timing and extent of tumour resections, chemotherapy regimens (neoadjuvant and adjuvant), number of courses of chemotherapy (both first line and subsequent regimens), radiotherapy use, glomerular filtration rate (GFR) and audiology monitoring, treatment sequelae and interventions, socio-economic status (SES) by annual household income, nature of follow-up and outcome. Nutritional parameters were defined according to the World Health Organization (WHO) Nutritional Landscape Information System (NLIS) Interpretation Guide, 2010,¹⁹ where moderate impact in each category was defined as an anthropometric measurement more than two standard deviations (SD) below the WHO Child Growth standards median and where severe impact was defined as more than three SD below that median. SES was assigned according to the Provincial Government of the Western Cape's Federal Acquisition Regulation No. 9 of 2017 (PGWC FAR9/2017). Tumours were staged according to the Children's Oncology Group staging system for extracranial germ cell tumours.² This information was centralised into a single dataset exported in comma-separated values format (.csv). Median follow-up was defined as the number of days from diagnosis to death or date last seen.

2.2 Statistical analysis

Stata Statistical Software v. 14 (StataCorp, College Station, TX) was used for consolidation, uniform recording and basic descriptive statistics. Survival analyses and output graphics were conducted with R Statistical Environment v. 3.5.2 (R Core Team, Vienna, Austria). The Kaplan–Meier procedure was used to estimate overall survival (OS) curves and survival at specific time points (1, 2 and 5 years) with associated 95% confidence intervals.^{20, 21} The log-rank test was applied to assess the existence of significant differences between survival curves in different subgroups. Multivariate Cox regression models were fitted to analyse the association of the OS and the event-free survival (EFS) with a series of potential prognostic factors.²² Nonlinear effects were analysed by introducing the relevant predictors as penalised smoothing splines.²³ This method was employed to assess whether there may be an age threshold beyond which patients had a less favourable outcome and also to establish a similar threshold for serum alpha-fetoprotein (AFP) level at diagnosis, which influenced OS or EFS. The Spearman test was used to establish an association between ordinal variables, in this case SES and stage. The proportional hazards assumption was tested by computing the scaled Schoenfeld residuals test.²⁴ A *p*-value <5% was used as a cutoff to define statistical significance. *p*-Values for relative hazards were calculated in a post hoc analysis comparing patients with AFP levels

above and below the identified thresholds in a Cox model, controlling for all other potential confounding factors.

2.3 Ethical approval

The study was approved by the Human Research Ethics Committee of the University of Cape Town (HREC 002/2018).

3 RESULTS

Two hundred eighteen patients diagnosed between 1 January 2000 and 31 December 2015 were included in the analysis with a median follow-up period of 1509 days (IQR 351–2837 days). Patient characteristics are shown in Table 1.

TABLE 1. Sample characteristics

Characteristics	Tumour site			Total	
	Testicular (n = 40)	Ovarian (n = 105)	EG (n = 72)	(n = 218) n	%
Sex					
Male	40	0	20	60	27.6
Female	0	106	52	158	72.4
Age					
0–4	35	13	59	107	49.1
5–9	2	29	6	37	17.0
10–14	2	58	6	66	30.2
≥15	1	6	1	8	3.7
Tumour site					
Ovarian	0	106	0	106	48.6
Testicular	40	0	0	40	18.3
Retroperitoneal	0	0	30	30	13.7
Abdomen	0	0	13	13	6.0
Mediastinal	0	0	13	13	6.0
Sacrococcygeal	0	0	11	11	6.0
Head and neck	0	0	5	5	2.3
Histology					
Yolk sac tumour	31	37	51	119	54.6
Mixed germ cell tumour	3	14	15	32	14.7
Embryonal carcinoma	3	5	0	8	3.7
Choriocarcinoma	0	1	1	2	0.9
Dysgerminoma	0	49	4	53	24.3
Seminoma	3	0	1	4	1.8
Stage					
I	19	27	13	59	27.0
II	5	22	10	37	17.0
III	9	39	27	75	34.4
IV	7	18	21	46	21.1
Missing	0	0	1	1	0.5
Stunted					
None	35	88	64	187	85.8
Moderate	1	12	3	16	7.3
Severe	2	4	5	11	5.0

Missing	2	2	0	4	1.8
Wasted					
None	38	91	61	190	87.1
Moderate	0	6	6	12	5.5
Severe	0	7	5	12	5.5
Missing	2	2	0	4	1.8
UWFA					
None	35	82	58	175	80.3
Moderate	4	17	10	31	14.2
Severe	0	5	4	9	4.1
Missing	1	2	0	3	1.4
AFP (ng/ml)					
0–9999	19	22	19	60	27.5
≥10,000	12	36	42	90	41.3
Missing	9	48	11	68	31.2
Treatment regimen					
No chemotherapy	15	7	4	26	11.9
JEb	13	38	37	88	40.4
PEb	1	2	4	7	3.2
BEP	10	53	22	85	39.0
Other	1	1	5	12	5.5

Abbreviations: AFP, alpha-fetoprotein; BEP, bleomycin, etoposide, cisplatin; EG, extragonadal; JEb, carboplatin, etoposide, bleomycin; PEb, cisplatin, etoposide, bleomycin; UWFA, under-weight for age.

3.1 Age and sex

The majority of patients were females, with a M:F ratio of 1:2.6. Males presented at a median age of 22.5 months (IQR 14.0–30.7 months) compared to females at 97 months (IQR 29.0–133.7 months). In the univariate analysis, sex was not a significant predictor of survival. However, in the multivariate analysis, females had a significantly lower risk of death (hazard ratio [HR] 0.284, $p = .037$). To test the hypothesis that among patients with MEGCTs, there existed a potential ‘threshold’ of age that characterised patients with worse outcomes, the models were refitted modelling age as a penalised spline. Both the analyses conducted on OS and EFS suggested that after controlling for all other potential confounding factors, age at diagnosis did not significantly affect the relative risk of death.

3.2 Site and histology

Ovarian masses predominated ($n = 106$; 48.6%), reflecting the proportionately larger number of female patients, followed by extragonadal sites (EG) ($n = 72$; 33%) and lastly testicular masses ($n = 40$; 18.3%). Yolk sac tumours were most common ($n = 119$; 54.6%), followed by dysgerminomas ($n = 53$; 24.3%), mixed germ cell tumours ($n = 32$; 13.8%), embryonal carcinomas ($n = 8$; 3.7%), seminomas ($n = 4$; 1.8%) and choriocarcinomas ($n = 2$; 0.9%). Neither tumour site nor histology ($p = .28$) was predictive of outcome.

3.3 Stage

Tumours by stage were represented as follows: stage 1 ($n = 59$; 27.1%), stage 2 ($n = 37$; 17.0%), stage 3 ($n = 75$; 34.4%) and stage 4 ($n = 46$; 21.1%). One patient was unstaged and demised shortly after presentation. Stage was highly predictive of outcome on both univariate

($p < .001$) and multivariate analysis, especially for patients with stage 3 ($p = .017$) and stage 4 ($p < .001$) disease (Table 2).

TABLE 2. Five-year OS and EFS by stage

Stage	OS (%)	EFS (%)	Test for differences in survival distributions (p -value)		Cox regression (multivariate analysis)
			OS	EFS	
I	96.0	94.1			
II	94.3	85	$p < .001$	$p < .001$	$p = .7195$
III	75.5	69.8			$p = .0171$
IV	60.1	55.2			$p < .001$

Abbreviations: EFS, event-free survival; OS, overall survival.

3.4 Nutritional status

The majority of patients were normally grown (187; 85.8%) but anthropometric data were missing for four patients. Sixteen patients were moderately stunted, whilst 11 were severely stunted. Thirty-one were moderately under-weight for age (UWFA) and nine were severely UWFA, whilst 12 patients were moderately and severely wasted, respectively. Although the majority of children were not stunted (87.3%), wasted (88.7%) or UWFA (81.3%), both stunting ($p < .0001$) and being UWFA ($p = .041$) appeared to be significant predictors of outcome on univariate analysis but could not be shown to be independently predictive of outcome on multivariate analysis.

3.5 Socio-economic status

The majority of patients declared their household income per annum (204/218; 93.5%): 71/204 (34.8%) patients were fully subsidised, 89/204 (43.6%) earned a yearly household income of less than USD 6600, nine of 204 (4.4%) earned an yearly household income of between USD 6600 and USD 23,000 and 35/204 (17.2%) earned in excess of USD 23,000 per year. Univariate analysis did not demonstrate SES as being a significant determinant of outcome ($p = .05$) but multivariate analysis revealed that patients who came from homes where household income exceeded USD 23,000 per year had a significantly lower risk of death (HR 0.071; $p = .039$) (Table 3). We also demonstrated a significant negative correlation between SES and stage (Spearman rho = $-.153$; $p = .03$), in that patients with higher SES presented with lower stage tumours. However, in the cox model, we adjusted for both SES and stage, revealing that the significant impact of SES on survival was in excess of any effect that could be explained by lower stage disease at diagnosis alone.

TABLE 3. Impact of socio-economic status as a prognostic factor for overall survival

Household income/year	n (%)	Overall survival	
		Univariate analysis	Multivariate analysis
Fully subsidised	71 (34.8)	$p = .05$	–
<USD 6600	89 (43.6)		$p = .6835$
USD 6600–23,100	9 (4.4)		$p = .8992$
>USD 23,100	35 (17.2)		$p = .039$

3.6 Tumour markers

One hundred eighty-six patients had secretory tumours with a demonstrably elevated tumour marker at diagnosis: AFP in 157 (81.8%), beta-human chorionic gonadotropin (β -HCG) in 28 (14.6%) and oestradiol in one patient (0.5%). Six patients had an elevated lactate dehydrogenase (LDH) in addition to another elevated tumour marker. Using the same methodology for age, we investigated the hypothesis of the existence of a threshold in the relationship between serum AFP levels at diagnosis and outcome. The analysis suggested negligible or no effect of serum AFP levels on OS or EFS for (relatively) small values of AFP, but a rapid increase of the hazard ratio for high values, such that serum AFP levels became significant as a prognostic factor for outcome at a serum AFP level \approx 33,000 ng/ml for OS and a serum AFP level \approx 21,600 ng/ml for EFS ($p = .044$).

3.7 Local control

3.7.1 Surgery

Two hundred two (93.1%) patients underwent surgery. One hundred thirty-one patients had (64.8%) complete resections, while 42/202 (20.7%) had incomplete resections. Of those who had incomplete resections, 12 (28.6%) died: nine (75%) of disease progression, one from an intraoperative aortic injury and two from other perioperative complications. Six patients (6/202; 2.9%) had irresectable tumours (two with stage III disease; four with stage IV disease). Four of the six died, three from disease and one from treatment-related complications. Ten patients refused surgery: five are dead, all of whom had stage III disease at diagnosis.

3.7.2 Radiotherapy

Eight patients underwent radiotherapy. Three patients received it as part of upfront therapy to facilitate resection, all with stage III disease. Two are survivors; one is lost to follow-up. Four patients received it as part of relapse therapy. Two are survivors and two are dead. It was used with palliative intent in one patient, who failed chemotherapy and had an irresectable tumour.

3.7.3 Chemotherapy

Twenty-five patients did not receive chemotherapy: 19/25 (76%) had stage I disease, of whom 16 are alive and three are lost to follow-up, presumed alive. Three had stage II disease, of whom two died of disease and one is a survivor. Two had stage III disease and one stage IV disease; all of whom died. Chemotherapy was administered to 192 patients: 88 (45.8%) patients received JEb, 85 (44.2%) BEP (bleomycin, etoposide, cisplatin), seven (3.6%) PEb and 12 (6.3%) a variety of nonstandard regimens with a mean of 4.7 courses (range 1–11 courses). One hundred medical treatment-related events occurred in 61 patients (Table S1), the most predictable acute effects being cytopenias²⁴ and febrile neutropenia (FN)¹¹ with hearing loss¹⁹ the commonest subacute/late effect.

3.7.4 Pre-cisplatin assessments

BEP or PEb was administered to 92 patients. Only nine (9.8%) had formal two-plasma sample radio-isotope GFR assessments, while calculated GFRs were performed in only six patients. Only 22/92 (23.9%) patients had formal audiology assessments. In the untested group, unavailability of services was cited for five patients. Hearing loss (ungraded) was reported in 19/22 (86.3%) patients.

3.7.5 Outcome

Patients who received chemotherapy had significantly better outcomes compared to those who did not, on both univariate ($p < .0007$) and multivariate ($p < .001$) analysis, irrespective of whether a carboplatin-based or cisplatin-based regimen was used.




FIGURE 1. Hazard ratios for overall survival according to multivariate analysis

In conclusion, only stage ($p < .001$), administration of chemotherapy ($p < .001$) and an elevated serum level of AFP of more than 33,000 ng/ml ($p = .002$) were independently predictive of OS. The result of the multivariate analysis is summarised in Figure 1. The 5-year OS for the group was acceptable at 80.4% with an EFS of 75.3%.

4 DISCUSSION

This national retrospective study demonstrated that stage, the use of chemotherapy and an elevated serum AFP level at diagnosis were independently predictive of OS. Additionally, female sex was associated with a significantly lower risk of death (HR 0.284; p -value .037), even after adjustment for tumour site and histology. The Malignant Germ Cell Tumour International Consortium (MaGIC) Study of 2015 reported that children with yolk sac tumours demonstrated a better outcome, although this was not found to be statistically significant. In addition, age and stage were significant predictors of outcome, but not sex.¹⁸ A recent epidemiological study of paediatric germ cell tumours conducted in Danish children revealed a similar female predominance (71%) but did not show any relationship between sex and risk of death.²⁵

In our study, tumour stage was significantly predictive of outcome ($p < .001$), especially for patients with advanced disease; stage III ($p = .0171$) and IV ($p < .001$). Our findings therefore correlated with the MaGIC analysis, which demonstrated a statistically significant relationship between stage IV disease and poor outcome, particularly in children over 11 years of age with advanced stage extragonadal tumours and metastatic ovarian tumours.¹⁸ Earlier studies also documented that advanced disease was predictive of poorer outcomes.^{26, 27}

In our cohort, a serum AFP level at diagnosis of more than 33,000 ng/ml was associated with a poorer OS, and a level of more than 21,000 ng/ml was associated with a poorer EFS ($p = .044$). Previously, serum AFP levels of more than 100,000 μ g/L have been associated poorer outcomes in children with hepatoblastoma.²⁸ The MaGIC analysis found that an elevated serum AFP level of more than 10,000 was associated with a poorer outcome, but it did not reach the threshold for statistical significance.¹⁸ AFP as a tumour marker has been described as tumour-associated rather than tumour-specific, given that its production can be elevated in a variety of both benign and malignant conditions in children and that the persistence of elevated levels acquired in utero, which usually normalises by 10 months of age ex utero, can sometimes persist until 2 years of age. The elevation of serum AFP levels cannot therefore be considered diagnostic exclusively and must be interpreted in concert with other factors.²⁹

The MaGIC study was able to demonstrate a threshold of age (11 years) beyond which outcomes were poorer using a bootstrap technique.¹⁸ We interrogated the same question using age modelled as a penalised spline because of our smaller sample size, and limiting it to patients with more advanced disease, but could not demonstrate a threshold of age beyond which outcomes were either more or less favourable.

In addition to female sex, higher household income, in excess of USD 23,000 per year, was associated with a significantly lower risk of death (HR 0.071; $p = .039$). We also showed a significant relationship between lower stage disease and higher SES ($p = .03$). However, early

presentation alone could not account for this association. This suggests that there are SES factors that may impact outcome during treatment. For example, access to transport may cause delays in chemotherapy or food insecurity may lead to malnutrition, negatively impacting immunity and the ability to combat infection or tolerate chemotherapy-related toxicity. Given our past of enforced racial segregation and the association between skin colour and poverty, it is critical to isolate these social determinants of health as skin colour is too easily invoked as a risk factor, when in reality these relate to privilege and access to care. In children with acute lymphoblastic leukaemia, a single-institutional study reported a higher risk of relapse in children from high poverty areas despite uniform treatment.³⁰ This is relevant, given our intention to embark on the implementation of a national treatment protocol for MEGCTs and will be instructive as we interrogate household income and maternal education as measures of SES. Also proving a significant relationship between SES and outcome strengthens our collective call for parity not only in service delivery and access to care but also for adequate social support for children, which is constitutionally enshrined, but not necessarily delivered in real time.

Analysis of our treatment interventions demonstrated that the surgical local control rate in our study was high with a complete resection rate (CRR) 64.8%. There was a 5% surgical refusal rate, which is a cause for concern considering that half of those patients died of disease as a result. In a systematic review of factors influencing refusal of therapy in adult cancer patients, discomfort of treatment, fear of side effects and transportation difficulties were cited as the most important contributing to refusal of surgery.³¹ In a recent study from Vietnam, adherence to cancer treatment in children was found to be determined by prognosis while being associated with local perceptions of cancer and the economic status of affected families.³² It is possible that a more rigorous informed consent and assent process such as that proposed for a national treatment protocol may help to allay the fears associated with paediatric cancer treatment specifically with respect to the surgery, which remains a cornerstone of care.

By comparison, the use of chemotherapy was strongly predictive of outcome with no single regimen performing better than any other (carboplatin vs. cisplatin based) and all regimens producing superior results compared to no chemotherapy at all ($p < .001$). This is corroborated by a recent MaGIC report demonstrating equipoise in contemporaneous trials using cisplatin- and carboplatin-based regimens in paediatric germ cell tumours.¹³

Radio-isotope GFR measurement is recommended as part of the standard-of-care guidelines for renal function assessment in paediatric oncology practice, as it impacts the dosing of platinum alkylators. As such standardising methodologies is critical.³³ Rates of formal GFR assessment (even in the absence of radio-isotope instruments) and also audiology assessment were infrequent, which is related to the lack of availability of or access to these services at all POUs across the country, as well as the large burden of patients presenting with advanced disease, whose poor performance status (renal or pulmonary) may preclude radio-isotope testing at the time diagnosis. Similarly, the use of calculated GFRs was low in the absence of formal radio-isotope testing. In a more recent study, calculated GFRs were found to either over- or underestimate the GFR. The recommendation was that radio-isotope GFR determination should remain standard of care for platin dosing to ensure accuracy.³⁴ Unfortunately, this may not always be possible in our setting and calculated GFRs may be the

best alternative. The value of calculated versus radio-isotope GFR measurement can be prospectively tested in the context of a national protocol and calculated GFRs as a surrogate for more accurate renal function evaluation could become standardised practice. In addition, to renal function assessment, significant numbers of hearing-impaired children may have evaded detection because of low rates of routine audiology testing, which has the potential to impact school performance and subsequently employability. This is notable because the unemployment rate for the hearing impaired in South Africa ranges from 21.2% to 35.3%, with low average annual household incomes of approximately USD 2000 for the moderately hearing impaired and USD 1500 for those with severe deficits,³⁵ placing them close to the upper-limit poverty line of USD 800 per household per year.³⁶

Despite these impediments, the 5-year OS for the entire cohort was very encouraging (80.4%) and patients who relapsed were salvaged (5-year EFS 75.3%).

We recognise that the sample size and hence the number of events were small and that this could have limited the statistical power to detect significant effects. Different treating centres made use of institutionally specific treatment protocols, often determined by resource constraints. Where space and bed capacity were at a premium, outpatient approaches, like JEb was favoured over inpatient regimens like BEP or PEb. Also age cutoffs for the admission of adolescents to paediatric wards varied widely between POU, resulting in an underrepresentation of older adolescents (16–19 years). Additionally, access to formal radio-isotope testing and audiology testing was fragmented, limiting the accurate assessment of renal function for platin dosing and hearing assessments.

This retrospective analysis was undertaken to assist with the development of a national protocol for children with MEGCTs in South Africa to standardise management and toxicity assessments. In the new national protocol, the choice of platinum will be influenced by several factors: first, previous local reports of the cost-effectiveness of JEb as an outpatient strategy¹⁶ and the significant relationship between SES and outcome reported here; second, the rates of platin-related ototoxicity reported here and that undertesting has potentially resulted in a failure to detect significant number of hearing-impaired children; and lastly, the availability of audiology services and nuclear medicine facilities, which are not ubiquitously available and tend to be clustered near larger POU in wealthier urban areas.

In addition, the finding of significant relationships between serum AFP levels and SES opens opportunities for the interrogation of these factors in a prospective way in the context of the new protocol, as we seek to provide guidance for best practice and as we advocate for social justice in medicine. Creating the discipline of standardised practice by teams with disease-specific expertise able to collaborate across institutional divides will improve paediatric oncology care in South Africa. As we look to the future, we hope to advocate for the establishment of bilateral funding agreements to open doors to children and families from across the subcontinent to receive expert, coordinated care at our national centres of excellence.

ACKNOWLEDGEMENTS

The work has been made possible by support from the National Research Foundation, NRF CSRU180429324830, the Harry Crossley Foundation, University of Cape Town, and The Professor Bongani Mayosi Netcare Clinical Scholarship. Special thanks to Professor David Reynders and Ms Judy Schoeman of the South African Children's Tumour Registry as well as Mrs Felicity Douglas and Ms Michelle Kannemeyer from the Red Cross War Memorial Children's Hospital in Cape Town. Dr Jaques van Heerden and the staff of the Paediatric Haematology Oncology, Department of Paediatrics and Child Health, Pietermaritzburg Metro Complex, University of Kwa-Zulu-Natal, Pietermaritzburg, South Africa are also acknowledged for their participation in the study.

CONFLICT OF INTEREST

The authors declare that there is no conflict of interest.

REFERENCES

1. Ulbright TM. Germ cell tumors of the gonads: a selective review emphasizing problems in differential diagnosis, newly appreciated, and controversial issues. *Mod Pathol.* 2005; 18(2): S61-S79.
2. Brodeur GM, Howarth CB, Pratt CB, Caces J, Hustu HO. Malignant germ cell tumors in 57 children and adolescents. *Cancer.* 1981; 48(8): 1890-1898.
3. National Cancer Institute Cancer Incidence and Survival Among Children and Adolescents: United States SEER Program 1975–1995. No 99-4649. SEER Program Bethesda. NIH Pub; 1999. Accessed April 4, 2020, <https://seer.cancer.gov/publications/childhood>
4. Cushing B, Perlman E, Marina N, Castleberry R. Principles and Practice of Pediatric Oncology. 5th ed. Lippincott Williams & Wilkins; 2006.
5. Huang J, Tan Y, Zhen Z, et al. Role of post-chemotherapy radiation in the management of children and adolescents with primary advanced malignant mediastinal germ cell tumors. *PLoS One.* 2017; 12(8):e0183219.
6. Duchesne GM, Stenning SP, Aass N, et al. Radiotherapy after chemotherapy for metastatic seminoma—a diminishing role. MRC Testicular Tumour Working Party. *Eur J Cancer.* 1997; 33(6): 829-835.
7. Einhorn LH, Donohue JP. Improved chemotherapy in disseminated testicular cancer. *J Urol.* 1977; 117(1): 65-69.
8. Einhorn LH, Donohue JP. Chemotherapy for disseminated testicular cancer. *Urol Clin North Am.* 1977; 4(3): 407-426.
9. Marina N, Fontanesi J, Kun L, et al. Treatment of childhood germ cell tumors. Review of the St. Jude experience from 1979 to 1988. *Cancer.* 1992; 70(10): 2568-2575.
10. Mann JR, Raafat F, Robinson K, et al. UKCCSG's germ cell tumour (GCT) studies: improving outcome for children with malignant extracranial non-gonadal tumours—carboplatin, etoposide, and bleomycin are effective and less toxic than previous regimens. United Kingdom Children's Cancer Study Group. *Med Pediatr Oncol.* 1998; 30(4): 217-227.

11. Pinkerton CR, Broadbent V, Horwich A, et al. 'JEB'—a carboplatin based regimen for malignant germ cell tumours in children. *Br J Cancer*. 1990; 62(2): 257-262.
12. Stern JW, Bunin N. Prospective study of carboplatin-based chemotherapy for pediatric germ cell tumors. *Med Pediatr Oncol*. 2002; 39(3): 163-167.
13. Frazier AL, Stoneham S, Rodriguez-Galindo C, et al. Comparison of carboplatin versus cisplatin in the treatment of paediatric extracranial malignant germ cell tumours: a report of the Malignant Germ Cell International Consortium. *Eur J Cancer*. 2018; 98: 30-37.
14. Kruger M, Hendricks M, Davidson A, et al. Childhood cancer in Africa. *Pediatr Blood Cancer*. 2014; 61(4): 587-592.
15. Stefan DC, Stones DK, Wainwright RD, et al. Childhood cancer incidence in South Africa, 1987–2007. *S Afr Med J*. 2015; 105(11): 939-947.
16. Hendricks M, Davidson A, Pillay K, Desai F, Millar A. Carboplatin-based chemotherapy and surgery: a cost effective treatment strategy for malignant extracranial germ cell tumours in the developing world. *Pediatr Blood Cancer*. 2011; 57(1): 172-174.
17. Marina N, London WB, Frazier AL, et al. Prognostic factors in children with extragonadal malignant germ cell tumors: a pediatric intergroup study. *J Clin Oncol*. 2006; 24(16): 2544-2548.
18. Frazier AL, Hale JP, Rodriguez-Galindo C, et al. Revised risk classification for pediatric extracranial germ cell tumors based on 25 years of clinical trial data from the United Kingdom and United States. *J Clin Oncol*. 2015; 33(2): 195-201.
19. WHO. Nutritional Landscape Information System (NLIS). Country Profile Indicators Interpretation Guide. WHO; 2010.
20. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. *J Am Stat Assoc*. 1958; 53: 457-481.
21. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. *Cancer Chemother Rep*. 1966; 50(3): 163-170.
22. Breslow NE. Analysis of survival data under the proportional hazards model. *Int Stat Rev*. 1975; 43(1): 45-57.
23. Eilers PHC, Marx BD. Flexible smoothing with B-splines and penalties. *Stat Sci*. 1996; 11: 89-121.
24. Grambsch PM, Therneau TM. Proportional hazards tests and diagnostics based on weighted residuals. *Biometrika*. 1994; 81: 515-526.
25. Evers M, Rechnitzer C, Graem N, et al. Epidemiological study of paediatric germ cell tumours revealed the incidence and distribution that was expected, but a low mortality rate. *Acta Paediatr*. 2017; 106(5): 779-785.
26. Mann JR, Raafat F, Robinson K, et al. The United Kingdom Children's Cancer Study Group's second germ cell tumor study: carboplatin, etoposide, and bleomycin are effective treatment for children with malignant extracranial germ cell tumors, with acceptable toxicity. *J Clin Oncol*. 2000; 18(22): 3809-3818.
27. Gobel U, Schneider DT, Calaminus G, et al. Multimodal treatment of malignant sacrococcygeal germ cell tumors: a prospective analysis of 66 patients of the German cooperative protocols MAKEI 83/86 and 89. *J Clin Oncol*. 2001; 19(7): 1943-1950.
28. von Schweinitz D, Bürger D, Bode U, et al. Results of the HB-89 study in treatment of malignant epithelial liver tumors in childhood and concept of a new HB-94 protocol. *Klin Padiatr*. 1994; 206(4): 282-288.

29. Schneider DT, Calaminus G, Göbel U. Diagnostic value of alpha 1-fetoprotein and beta-human chorionic gonadotropin in infancy and childhood. *Pediatr Hematol Oncol.* 2001; 18(1): 11-26.
30. Bona K, Blonquist TM, Neuberg DS, Silverman LB, Wolfe J. Impact of socioeconomic status on timing of relapse and overall survival for children treated on dana-farber cancer institute all consortium protocols (2000–2010). *Pediatr Blood Cancer.* 2016; 63(6): 1012-1018.
31. Martine TE, Tapscott B, Fitch M, et al. A systematic review of factors influencing older adults' decision to accept or decline cancer treatment. *Cancer Treat Rev.* 2015; 41(2): 197-215.
32. Lan BN, Castor A, Wiebe T, Toporski J, Moell C, Hagander L. Adherence to childhood cancer treatment: a prospective cohort study from Northern Vietnam. *BMJ Open.* 2019; 9(8):e026863.
33. Chinnaswamy G, Cole M, Boddy AV, et al. Estimation of renal function and its potential impact on carboplatin dosing in children with cancer. *Br J Cancer.* 2008; 99(6): 894-899.
34. Shepherd STC, Gillen G, Morrison P, et al. Performance of formulae based estimates of glomerularfiltration rate for carboplatin dosing in stage 1 seminoma. *Eur J Cancer.* 2014; 50(5): 944-952.
35. Statistics South Africa; 2011. Accessed February 4, 2020. <http://www.statssa.gov.za/?p=3180>
36. Stats SA National Poverty Lines. Statistical Release P0310.1 [Internet]. Statistics South Africa; 2018. Accessed February 4, 2020, <http://www.statssa.gov.za/publications/P03101/P031012018.pdf>